Oncopeptides AB (publ)

OM:ONCO Stock Report

Market Cap: SEK 324.5m

Oncopeptides Management

Management criteria checks 2/4

Oncopeptides' CEO is Sofia Heigis, appointed in Aug 2023, has a tenure of 1.33 years. total yearly compensation is SEK3.18M, comprised of 55.3% salary and 44.7% bonuses, including company stock and options. directly owns 0.009% of the company’s shares, worth SEK29.83K. The average tenure of the management team and the board of directors is 1.9 years and 7.2 years respectively.

Key information

Sofia Heigis

Chief executive officer

SEK 3.2m

Total compensation

CEO salary percentage55.3%
CEO tenure1.3yrs
CEO ownership0.009%
Management average tenure1.9yrs
Board average tenure7.2yrs

Recent management updates

Recent updates

An Intrinsic Calculation For Oncopeptides AB (publ) (STO:ONCO) Suggests It's 45% Undervalued

Jun 18
An Intrinsic Calculation For Oncopeptides AB (publ) (STO:ONCO) Suggests It's 45% Undervalued

Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely

Feb 29
Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely

Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?

Nov 14
Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?

We Think Oncopeptides (STO:ONCO) Needs To Drive Business Growth Carefully

Jul 26
We Think Oncopeptides (STO:ONCO) Needs To Drive Business Growth Carefully

Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?

Mar 25
Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?

Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?

Nov 23
Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Sofia Heigis's remuneration changed compared to Oncopeptides's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-SEK 282m

Jun 30 2024n/an/a

-SEK 263m

Mar 31 2024n/an/a

-SEK 246m

Dec 31 2023SEK 3mSEK 2m

-SEK 249m

Compensation vs Market: Sofia's total compensation ($USD287.94K) is about average for companies of similar size in the Swedish market ($USD231.71K).

Compensation vs Earnings: Insufficient data to compare Sofia's compensation with company performance.

CEO

Sofia Heigis (44 yo)

1.3yrs

Tenure

SEK 3,180,000

Compensation

Ms. Sofia Heigis, M.sc, was Chief Commercial Officer and Managing Director of Germany at Oncopeptides AB (publ) since 2022 until 07 August 2023 and also serves as its CEO since 07 August 2023. Ms. Heigis j...

Leadership Team

NamePositionTenureCompensationOwnership
Sofia Heigis
Chief Executive Officer1.3yrsSEK 3.18m0.0093%
SEK 30.3k
Jakob Lindberg
Chief Scientific Officer1.9yrsSEK 4.84m0.40%
SEK 1.3m
Rolf Larsson
Founderno datano datano data
Rolf Lewensohn
Founderno datano datano data
Joachim Gullbo
Founderno datano datano data
Kristina Luthman
Founderno datano datano data
Hans Ehrsson
Founderno datano datano data
Peter Nygren
Founderno datano datano data
Henrik Bergentoft
Chief Financial Officer1.1yrsno datano data
Eva Nordström
COO & Deputy MD4.9yrsno data0.056%
SEK 181.3k
David Augustsson
Director of IR & Communications1.9yrsno datano data
Sara Svardgren
Head of Human Resources6.6yrsno data0.000040%
SEK 129.8

1.9yrs

Average Tenure

50yo

Average Age

Experienced Management: ONCO's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Per Wold-Olsen
Independent Chairman of the Board6.6yrsSEK 1.63m0.23%
SEK 750.4k
Per Anders Samuelsson
Independent Director12.9yrsSEK 355.00kno data
Cecilia Wennborg
Independent Director7.8yrsSEK 682.50k0.026%
SEK 83.1k
Lori Kunkel
Member of Clinical Advisory Boardno datano datano data
Jarl Jungnelius
Independent Director13.7yrsSEK 627.50k0.047%
SEK 152.4k
Brian Stuglik
Independent Director6.6yrsSEK 755.00kno data
Christian Jacques
Member of Clinical Advisory Boardno datano datano data
Jennifer Jackson
Independent Director6yrsSEK 755.00kno data
Axel Glasmacher
Member of Clinical Advisory Boardno datano datano data
Paul Richardson
Member of Clinical Advisory Boardno datano datano data

7.2yrs

Average Tenure

66yo

Average Age

Experienced Board: ONCO's board of directors are considered experienced (7.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 19:45
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oncopeptides AB (publ) is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Erik HultgårdCarnegie Investment Bank AB
Patrik LingDNB Markets
Robert BurnsH.C. Wainwright & Co.